瘤后炎症和血管光滑肌肉细胞功能障碍在败血症诱导的心肌病的相互作用
1Department of Critical Care Medicine, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.
Frontiers in immunology
|April 25, 2025
概括
癌症患者的败血症诱导心肌病 (SIC) 与DVL1基因有关,DVL1基因可能是治疗点. 迪戈辛在治疗SIC和改善免疫治疗结果方面具有潜力.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 败血症引起的心肌病 (SIC) 是癌症患者的主要并发症,导致心力衰竭和死亡率.
- 败血症,瘤炎症和心脏功能障碍之间的分子联系尚未完全理解.
- 这项研究调查了SIC中瘤后炎症和瘤内异质性的作用.
研究的目的:
- 阐明炎症,瘤异质性和SIC中血管光滑肌细胞 (VSMC) 功能障碍之间的相互作用.
- 评估运动和药理干预措施对SIC的治疗潜力.
- 确定关键的分子参与者和涉及SIC病变发生的途径.
主要方法:
- 对NCBI和GEO数据库的转录组分析,以确定SIC.中的差异表达基因 (DEGs).
- 权重基因共同表达网络分析 (WGCNA),基因本体学 (GO) 和KEGG通路分析.
- 分子对接,动态模拟和免疫透分析 (TIMER 2.0,DepMap) 来评估DVL1的作用.
主要成果:
- 鉴定DVL1基因是SIC和各种癌症中核心,上调基因,与预后不佳和炎症有关.
- 分子对接表明,迪戈辛可以与DVL1结合,有可能减少SIC中的氧化应激.
- WGCNA确定了一种与SIC相关的DVL1基因模块,免疫分析揭示了DVL1对免疫细胞模式和免疫疗法耐药性的影响.
结论:
- DVL1是SIC和癌症的关键调节剂,代表了一个潜在的治疗标.
- 与运动相结合的向治疗可以减少癌症患者的败血症相关炎症.
- 迪戈辛为SIC治疗和改善免疫治疗结果提供了进一步的体内和临床研究.
相关概念视频
The Tumor Microenvironment
6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K


